<DOC>
	<DOC>NCT02392559</DOC>
	<brief_summary>A study to assess safety and efficacy of evolocumab (AMG-145) in paediatric subjects aged 10-17 years diagnosed with heterozygous familial hypercholesterolemia.</brief_summary>
	<brief_title>Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders</brief_title>
	<detailed_description>A study to evaluate the effect of 24 weeks of subcutaneous (SC) evolocumab compared with placebo,when added to standard of care, on percent change from baseline in low‑density lipoprotein cholesterol (LDL-C) in pediatric subjects 10 to 17 years of age with HeFH</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Male or female ≥ 10 to ≤ 17 years of age (before 18th birthday) Diagnosis of heterozygous familial hypercholesterolemia On an approved statin with stable optimized dose for ≥ 4 weeks Other lipidlowering therapy stable for ≥ 4 weeks (fibrates must be stable for ≥ 6 weeks) Fasting LDLC ≥ 130 mg/dL (3.4 mmol/L) Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L) Type 1 diabetes, or type 2 diabetes that is or poorly controlled Uncontrolled hyperthyroidism or hypothyroidism Cholesterylester transfer protein (CETP) inhibitor in the last 12 months, or mipomersen or lomitapide in the last 5 months Previously received evolocumab or any other investigational therapy to inhibit PCSK9. Lipid apheresis within the last 12 weeks prior to screening. Homozygous Familial Hypercholesterolemia</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Elevated Cholesterol</keyword>
	<keyword>High Cholesterol</keyword>
	<keyword>Heterozygous Familial Hypercholesterolemia</keyword>
	<keyword>PCSK9 mutations</keyword>
	<keyword>Paediatric</keyword>
	<keyword>pediatric</keyword>
	<keyword>Childhood Familial Hypercholesterolemia</keyword>
</DOC>